Trials / Conditions / Sickle Cell Disease

Sickle Cell Disease

796 registered clinical trials studyying Sickle Cell Disease — 140 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, NCT05951205	Vertex Pharmaceuticals Incorporated	Phase 3
Not Yet Recruiting	Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickl NCT07498309	University Hospital, Rouen	Phase 3
Not Yet Recruiting	STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE NCT07341022	Hospital Israelita Albert Einstein	Phase 1 / Phase 2
Recruiting	Functional Ovarian Reserve in Sickle Cell Disease NCT07392216	St. Jude Children's Research Hospital	—
Not Yet Recruiting	Transcranial Photobiomodulation Treatment in Patients With Sickle Cell Disease NCT06797583	St. Jude Children's Research Hospital	N/A
Recruiting	Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease NCT06979492	Emory University	Phase 4
Recruiting	Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults NCT07369024	Mohsen Saidinejad	Phase 2
Enrolling By Invitation	Open-Label Extension Study to Pioneer Study 6058-SCD-101 NCT07401823	Fulcrum Therapeutics	Phase 2
Recruiting	Alendronate for Osteonecrosis in Adults With Sickle Cell Disease NCT06016634	University of California, Davis	Phase 2
Recruiting	Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care NCT07246265	University Hospital, Tours	N/A
Not Yet Recruiting	SickleFit Randomized Control Trial NCT07442851	Duke University	N/A
Withdrawn	A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy NCT06286046	Agios Pharmaceuticals, Inc.	Phase 2
Not Yet Recruiting	Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease NCT07436767	Institute of Hematology & Blood Diseases Hospital, China	N/A
Recruiting	Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vi NCT07432867	Assistance Publique - Hôpitaux de Paris	Phase 1 / Phase 2
Recruiting	Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial NCT06260891	University of California, San Francisco	Phase 2
Recruiting	Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease NCT07222475	Mayo Clinic	N/A
Recruiting	Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) NCT07224360	CSL Behring	Phase 2
Recruiting	Early Life Exposures Among Children With Sickle Cell Disease NCT05377372	University of Alabama at Birmingham	N/A
Not Yet Recruiting	Optimal Timing of Ketamine Initiation for SCD Pain NCT07450430	Boston Children's Hospital	Phase 3
Withdrawn	The Sequestration of Holistic Stress Management Techniques for Adults NCT06098755	Goddess Zena I. Jones	N/A
Recruiting	Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle C NCT07247188	Sanofi	Phase 3
Recruiting	Stress Management and Mindfulness Intervention for Patients With Sickle Cell Disease NCT07316478	University of Pennsylvania	N/A
Recruiting	Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease NCT06919224	Ohio State University	N/A
Recruiting	A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) NCT07187973	Disc Medicine, Inc	Phase 1
Not Yet Recruiting	Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease NCT07252050	University of Colorado, Denver	Phase 1 / Phase 2
Not Yet Recruiting	Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype NCT07282210	Biossil Inc.	Phase 2
Recruiting	A Long-term Follow-up Study in Patients Who Received BEAM-101 NCT07373639	Beam Therapeutics Inc.	—
Recruiting	Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease NCT07431398	Fulcrum Therapeutics	Phase 1
Recruiting	Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease NCT07402811	University of Illinois at Chicago	N/A
Recruiting	Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies NCT06647979	Daniel Bauer	Phase 1
Recruiting	Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease NCT07226219	St. Jude Children's Research Hospital	Phase 1
Recruiting	Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease NCT06555939	Boston Children's Hospital	N/A
Withdrawn	Biotin-Acridine Red Cell Exchange Kinetics NCT07155031	Cerus Corporation	Phase 2
Recruiting	Early Screening and Treatment of Heart Complication in Sickle Cell Disease NCT07023666	Inova Health Care Services	Phase 2
Not Yet Recruiting	Outcomes of Vaso-occlusive Crisis in Pediatric Sickle Cell Disease NCT07200869	Assiut University	—
Recruiting	Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0 NCT06725550	Indiana University	N/A
Recruiting	Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor NCT04774536	Mark Walters, MD	Phase 1 / Phase 2
Recruiting	The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease NCT06975865	Sanofi	Phase 3
Recruiting	Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suf NCT07090668	Emory University	N/A
Not Yet Recruiting	A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Eme NCT06989567	Asklepion Pharmaceuticals, LLC	Phase 3
Not Yet Recruiting	CS-206 in Patients With Sickle Cell Disease NCT07000318	Children's Hospital of Fudan University	EARLY_Phase 1
Recruiting	Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individua NCT06944067	National Human Genome Research Institute (NHGRI)	—
Completed	A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants NCT07023029	Novo Nordisk A/S	Phase 1
Recruiting	PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE P NCT06923111	Nova Laboratories Limited	—
Not Yet Recruiting	Minocycline in Neurocognitive Outcomes - Sickle Cell Disease NCT05605366	University of Cincinnati	Phase 1
Recruiting	A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD NCT06924970	Agios Pharmaceuticals, Inc.	Phase 2
Recruiting	Sickle Cell, Pain and Mediterranean Diet NCT06886477	University of Illinois at Chicago	N/A
Recruiting	Ultrasound Acute Chest Syndrome Sickle Cell Disease NCT06880679	Indiana University	N/A
Recruiting	Cannabidiol in Sickle Cell Disease NCT06930703	Icahn School of Medicine at Mount Sinai	Phase 1 / Phase 2
Recruiting	Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain NCT05519111	Icahn School of Medicine at Mount Sinai	Phase 2
Recruiting	MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease NCT06853158	University of California, Irvine	N/A
Not Yet Recruiting	Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease NCT06818266	Assistance Publique - Hôpitaux de Paris	Phase 3
Recruiting	School Readiness Intervention for Preschool Children With Sickle Cell Disease NCT06367192	St. Jude Children's Research Hospital	N/A
Recruiting	Gene Editing For Sickle Cell Disease NCT06506461	St. Jude Children's Research Hospital	Phase 1
Recruiting	Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Ch NCT07356050	Children's Hospital Medical Center, Cincinnati	—
Recruiting	Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain NCT06374238	University of Pittsburgh	N/A
Recruiting	Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease NCT06770010	Children's National Research Institute	N/A
Completed	Opioid Prescribing in the Emergency Department for Sickle Cell Disease NCT06835335	Centre Hospitalier Universitaire de Nīmes	—
Recruiting	A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease NCT06612268	Novo Nordisk A/S	Phase 3
Completed	Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2) NCT06561061	Indiana University	Phase 2 / Phase 3
Recruiting	Impact of Regional Anesthesia on Inflammatory Mechanisms During Vaso-occlusive Crisis in Sickle Cell Patients NCT07001189	Centre Hospitalier Universitaire de la Guadeloupe	—
Recruiting	Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in NCT06578507	Theravia	Phase 2
Completed	The Feasibility of the Pray Until Something Happens (PUSH) Intervention-OUTPATIENT NCT06580067	University of Florida	N/A
Recruiting	A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassa NCT06609226	Novo Nordisk A/S	Phase 3
Recruiting	Adapting the FACETS Program to Sickle Cell Disease NCT06650813	Versailles Hospital	N/A
Recruiting	Integrative Training Program for Pediatric Sickle Cell Pain NCT06691867	Emory University	N/A
Not Yet Recruiting	Evaluation of the Impact of Red Blood Cell Exchange on Thrombo-inflammation in Sickle Cell Disease NCT06769139	University Hospital, Toulouse	—
Not Yet Recruiting	Pilot Study on the Value of Bedside Pleuropulmonary Ultrasound in Patients With Sickle Cell Disease Presenting NCT06755385	University Hospital, Grenoble	—
Not Yet Recruiting	Testing the Sickle Cell Caregiver Collaboration for Child Development (SCCCD) Intervention NCT06562439	Washington University School of Medicine	N/A
Recruiting	Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease NCT06635902	Suvankar Majumdar	Phase 2
Recruiting	Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sick NCT05904093	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1
Recruiting	Pulmonary Functions in Sickle Cell Disease: Response to Acu-TENS NCT06757829	Cairo University	N/A
Completed	Cohort Study of Sickle Cell Patients Evaluating Analgesic Strategies and Their Consequences NCT06650059	Assistance Publique - Hôpitaux de Paris	—
Recruiting	Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy NCT06689800	Washington University School of Medicine	N/A
Recruiting	Empowering Adolescents and Young Adults With Sickle Cell Disease as Partners in Treatment Decision Making (EMP NCT05383911	Nemours Children's Clinic	N/A
Recruiting	Allo HSCT for High Risk Hemoglobinopathies NCT06872333	Masonic Cancer Center, University of Minnesota	Phase 2
Recruiting	SCD Stem Cell Mobilization and Apheresis Using Motixafortide NCT06442761	St. Jude Children's Research Hospital	Phase 1
Active Not Recruiting	Prevention of Malnutrition in Children With Sickle Cell Disease NCT06397118	Vanderbilt University Medical Center	N/A
Recruiting	Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Oc NCT06184126	University of Maryland, Baltimore	N/A
Enrolling By Invitation	ATHNdataset Registry NCT06820515	American Thrombosis and Hemostasis Network	—
Recruiting	A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent NCT06439082	Novartis Pharmaceuticals	Phase 3
Recruiting	Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders NCT06147414	Assistance Publique - Hôpitaux de Paris	—
Enrolling By Invitation	Decision-Making and Quality of Life Surrounding Hematologic Disease and Gene Therapy NCT06664541	Georgetown University	—
Not Yet Recruiting	Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease NCT06579703	Children's Blood and Cancer Center at Dell Children's Medical Center	Phase 4
Recruiting	Effect of EMDR for Reduction of Pain Interference in Children With Sickle Cell Disease NCT07001631	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	N/A
Recruiting	Peripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease NCT06477289	St. Jude Children's Research Hospital	—
Recruiting	Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain NCT06773715	Louisiana State University Health Sciences Center in New Orleans	N/A
Recruiting	CS-206 in Patients With Sickle Cell Disease NCT06565026	CorrectSequence Therapeutics Co., Ltd	EARLY_Phase 1
Enrolling By Invitation	SCRIPT: Sickle Cell Risk in Pregnancy Tool NCT06529042	Mount Sinai Hospital, Canada	—
Recruiting	Long-term Endurance Training in Sickle Cell Disease Patients: Impact on Clinical Profile, Physical Fitness, an NCT06823219	Assistance Publique - Hôpitaux de Paris	N/A
Completed	A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants NCT06581627	Novo Nordisk A/S	Phase 1
Not Yet Recruiting	Development and Evaluation of an Information Management System and Communication System for Population-wide Po NCT06563440	Makerere University	N/A
Recruiting	A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease NCT06546670	Novartis Pharmaceuticals	Phase 1 / Phase 2
Recruiting	Stroke Prevention in Nigeria 2 Trial NCT06526117	Vanderbilt University Medical Center	Phase 4
Recruiting	Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease NCT06399107	Essen Biotech	Phase 1 / Phase 2
Enrolling By Invitation	Clinical Study of BRL-101 in Severe SCD NCT06300723	Bioray Laboratories	N/A
Recruiting	Predictors of Pain in Sickle Cell Disease NCT06139510	Duke University	N/A
Recruiting	Applying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness NCT06264700	Nationwide Children's Hospital	N/A
Not Yet Recruiting	Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia NCT05469828	Children's Hospital Los Angeles	Phase 1 / Phase 2
Recruiting	mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria NCT06318143	New York University	N/A
Recruiting	Lung Ultrasound in Pediatric Acute Chest Syndrome NCT06497153	Assistance Publique - Hôpitaux de Paris	—
Recruiting	Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients NCT07000747	Centre Hospitalier Universitaire de la Guadeloupe	—
Enrolling By Invitation	A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Wh NCT06363760	Editas Medicine, Inc.	—
Not Yet Recruiting	Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease NCT06287086	Bioray Laboratories	N/A
Recruiting	FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases NCT06539169	xCures	—
Recruiting	Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling NCT06313398	National Heart, Lung, and Blood Institute (NHLBI)	EARLY_Phase 1
Suspended	Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adul NCT05457790	National Cancer Institute (NCI)	N/A
Not Yet Recruiting	Comparative Health Status and Quality of Life of Patients With Sickle Cell Disease (SCD) Who Underwent Matched NCT06351462	Assistance Publique - Hôpitaux de Paris	N/A
Unknown	Support Strategies for Parents During the First Year Following Their Child's Diagnosis of Sickle Cell Disorder NCT06251843	King's College London	—
Not Yet Recruiting	Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease NCT06287099	Bioray Laboratories	N/A
Active Not Recruiting	Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor NCT06155500	Novartis Pharmaceuticals	Phase 1
Recruiting	SMYLS Multi-site Trial NCT06035939	Medical University of South Carolina	N/A
Recruiting	Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibod NCT06358638	Children's National Research Institute	Phase 2
Recruiting	LEARNER- Low dosE AspiRiN prEterm tRial (Angola) NCT06417411	Instituto Nacional de Investigacao em Saude, Angola	Phase 1 / Phase 2
Completed	Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease NCT05725902	Novo Nordisk A/S	Phase 2
Active Not Recruiting	Acupressure in Patients With Sickle Cell Disease NCT06511453	Indiana University	N/A
Completed	Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease NCT06345638	University of Pennsylvania	—
Active Not Recruiting	Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease NCT05861453	Afimmune	Phase 2
Unknown	Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis NCT04614610	Community Medical Center, Toms River, NJ	Phase 2
Active Not Recruiting	Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ NCT06145282	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1 / Phase 2
Recruiting	Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa NCT05285917	Brown University	Phase 3
Recruiting	Sickle Cell Children's Exercise Study (SuCCESs) NCT06074198	University of Maryland, Baltimore	N/A
Active Not Recruiting	Realizing Effectiveness Across Continents With Hydroxyurea NCT06171217	Children's Hospital Medical Center, Cincinnati	Phase 2
Unknown	The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease NCT06158945	Sohag University	—
Active Not Recruiting	Assessing Physical Function in Sickle Cell Patients Taking Voxelotor NCT06023199	Inova Health Care Services	Phase 2
Recruiting	Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET NCT05583721	St. Jude Children's Research Hospital	Phase 2
Completed	COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease NCT05998824	Duke University	N/A
Active Not Recruiting	Study on Use of Omega-3 Fatty Acids to Improve Outcomes in Individuals With Sickle Cell Disease NCT05758766	University of Alabama at Birmingham	N/A
Unknown	Patient and Public Involvement and Engagement in Research With Children and Young People With Sickle Cell Diso NCT06293222	King's College London	—
Withdrawn	Voxelotor Brain Oxygenation and Neurocognitive Study NCT05228821	Pfizer	Phase 4
Completed	Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Dis NCT05618301	Washington University School of Medicine	Phase 1
Unknown	Enablers and Barriers to Hydroxyurea Use for Sickle Cell Disease Jamaica NCT05909657	The University of The West Indies	—
Unknown	The Living With a Long-Term Condition Study NCT06072287	King's College London	—
Recruiting	A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediat NCT05953584	Forma Therapeutics, Inc.	Phase 2
Completed	The Role of Red Cell Characteristics, Angiogenesis, Viscosity and Oxygenation in the Pathophysiology of Sickle NCT06396403	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	—
Recruiting	Effects of the Contraceptive Implant in Women With Sickle Cell Disease NCT05730205	University of Pennsylvania	Phase 4
Completed	Development and Adaptation of I-STRONG for SCD NCT06110754	Emory University	N/A
Recruiting	Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease NCT06385886	RTI International	—
Completed	Use of Macrolides in Acute Chest Syndrome: A Multicenter Retrospective Study NCT07037706	Centre Hospitalier de Saint-Denis	—
Recruiting	Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Disease NCT05810181	St. Jude Children's Research Hospital	—
Completed	Hydroxyurea and EPO in Sickle Cell Disease NCT05451940	Julia Xu	Phase 1 / Phase 2
Completed	High Dose Vitamin D Supplementation in Children With Sickle Cell Disease NCT06274203	Zagazig University	N/A
Unknown	Genetic and Haematological Modifiers of SCD Severity in Kaduna State, Northern Nigeria NCT05837871	Ahmadu Bello University Teaching Hospital	—
Unknown	Clonidine With Morphine in Patient Controlled Analgesia Pump in Vaso-Occlusive Crisis in Sickle Cell Disease P NCT05848531	Centre Hospitalier Universitaire Saint Pierre	Phase 4
Completed	Voxelotor CYP and Transporter Cocktail Interaction Study NCT05981365	Pfizer	Phase 1
Active Not Recruiting	Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients NCT05791591	LGD	N/A
Recruiting	Tocilizumab for Acute Chest Syndrome NCT05640271	University of Chicago	Phase 2
Active Not Recruiting	Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD) NCT05789355	LGD	N/A
Withdrawn	Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor NCT04817345	St. Jude Children's Research Hospital	Phase 2
Completed	Gerofit Exercise Intervention for Older Adults With Sickle Cell Disease (SICKLE-FIT Study) NCT05714098	Duke University	N/A
Unknown	Hemolysis Related Complications in SCD. A Phase II Study With Voxelotor NCT05199766	Assistance Publique - Hôpitaux de Paris	Phase 2
Recruiting	RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease NCT05392894	King's College Hospital NHS Trust	Phase 3
Recruiting	A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to NCT05736419	Memorial Sloan Kettering Cancer Center	Phase 2
Recruiting	Optimizing the Management of Sickle Cell Patients on Hydroxyurea: The Value of Therapeutic Pharmacological Mon NCT06464458	University Hospital, Strasbourg, France	N/A
Recruiting	Arterial Function Parameters and Transcranial Doppler Velocity in Paediatric Patients With Sickle Cell Disease NCT05748717	The University of The West Indies	—
Completed	ORCHARD- Optimising Home Assessment of Rural Patients NCT05732922	University of Aberdeen	N/A
Active Not Recruiting	Inflammation, Platelets and Sickle Cell Disease NCT05646888	University Hospital, Toulouse	—
Recruiting	A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disea NCT06198712	Forma Therapeutics, Inc.	Phase 2
Terminated	GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD) NCT05632354	Pfizer	Phase 2 / Phase 3
Completed	A GBT021601 ADME Microtracer Study in Healthy Volunteers NCT05718687	Pfizer	Phase 1
Recruiting	Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease NCT05099874	Children's National Research Institute	N/A
Completed	Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Se NCT06662825	Novartis	—
Terminated	AB1 in Adult Patients with Sickle Cell Disease (SCD) NCT05261711	Nirmish Shah	Phase 1 / Phase 2
Active Not Recruiting	CHOICES3: Sickle Cell Disease Parenting CHOICES NCT05292781	University of Florida	N/A
Active Not Recruiting	Lipid Balance in Adult Sickle Cell Patients NCT05780775	Centre Hospitalier Universitaire de la Guadeloupe	N/A
Completed	Screening for Renal Complications in Children and Young Adults With Major Sickle Cell Disease NCT05211037	Centre Hospitalier Universitaire de Nice	N/A
Recruiting	PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD NCT04925492	Enrico Novelli	Phase 1
Completed	Mindfulness and Yoga Therapy for Acute Pain in Sickle Cell Disease NCT05572294	University of Texas Southwestern Medical Center	N/A
Active Not Recruiting	Sickle Cell Disease (SCD) Bone Pain Study NCT05283148	University of California, Davis	N/A
Unknown	Osteopathic Manipulation in the Management of Pain Associated With Sickel Cell Disease NCT05632289	College Osteopathique de Provence Aix-Marseille	N/A
Active Not Recruiting	Synthetic Generation of Hematological Data Over Federated Computing Frameworks: SCD Use Case NCT06794281	Hospital Universitari Vall d'Hebron Research Institute	—
Withdrawn	SCD Fit Homebase Program NCT05228756	University of Alabama at Birmingham	N/A
Unknown	Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Sickle Cell Anemia NCT05053932	Centre Hospitalier Intercommunal Creteil	—
Unknown	Nano-rheological Biomarkers for Patients With Sickle Cell Disease (SCD) Versus Control Subjects (Other Constit NCT05530239	University Hospital, Grenoble	—
Recruiting	Study of the Role of Genetic Modifiers in Hemoglobinopathies NCT05799118	Cyprus Institute of Neurology and Genetics	—
Recruiting	A Phase 2/3 Study in Adult and Adolescent Participants With SCD NCT05431088	Pfizer	Phase 2 / Phase 3
Completed	Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada NCT05506358	University of British Columbia	N/A
Unknown	Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Diseas NCT05289700	University Hospital, Geneva	Phase 3
Completed	Baby Detect : Genomic Newborn Screening NCT05687474	Centre Hospitalier Universitaire de Liege	—
Active Not Recruiting	BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease NCT05456880	Beam Therapeutics Inc.	Phase 1 / Phase 2
Recruiting	Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait NCT07083531	UConn Health	—
Recruiting	Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thal NCT05477563	Vertex Pharmaceuticals Incorporated	Phase 3
Unknown	Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA NCT05334576	Andria Ford	N/A
Completed	L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity NCT05470998	Tanta University	Phase 3
Unknown	Do Alemtuzumab Levels Predict T Cell Chimerism After MSD SCT for SCD? NCT05905770	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	—
Active Not Recruiting	TMLI and Alemtuzumab for Treatment of Sickle Cell Disease NCT05384756	City of Hope Medical Center	Phase 1
Recruiting	Cooperative Assessment of Late Effects for SCD Curative Therapies NCT05153967	Vanderbilt University Medical Center	—
Active Not Recruiting	A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001) NCT05353647	David Williams	Phase 2
Completed	Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease. NCT05470270	Theravia	Phase 2
Completed	Research Study Investigating How Well NDec Works in People With Sickle Cell Disease NCT05405114	Novo Nordisk A/S	Phase 2
Unknown	The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle C NCT05214105	University of Tennessee	—
Recruiting	Cognitive Remediation Intervention to Prepare for Transition of Care NCT05336201	University of Alabama at Birmingham	Phase 2
Terminated	Voxelotor Neurocognitive Function Study NCT05228834	Pfizer	Phase 3
Terminated	Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease NCT05445128	Ensoma	Phase 2
Unknown	Pilates Physical Activity in Sickle Cell Disease NCT05519852	Cairo University	N/A
Unknown	Brain Structure and Neurocognitive Development in Sickle Cell Disease; a Longitudinal Cohort Study (BRICK Stud NCT05564845	Dr. Marjon H. Cnossen MD PhD	—
Active Not Recruiting	Alternative Dosing And Prevention of Transfusions (ADAPT) NCT05662098	Children's Hospital Medical Center, Cincinnati	EARLY_Phase 1
Terminated	THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) NCT05033314	University Health Network, Toronto	Phase 3
Terminated	Resolution of Sickle Cell Leg Ulcers With Voxelotor NCT05561140	Pfizer	Phase 3
Recruiting	Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease NCT05170412	National Institutes of Health Clinical Center (CC)	—
Completed	Efficacy of Designed Exercise Program on Pain and Quality of Sleeping in Patient With Sickle Cell Disease Anem NCT05894161	Imam Abdulrahman Bin Faisal University	N/A
Active Not Recruiting	Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) NCT05329649	Vertex Pharmaceuticals Incorporated	Phase 3
Terminated	A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease NCT05348915	Pfizer	Phase 3
Completed	A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease NCT04987489	Forma Therapeutics, Inc.	Phase 2
Completed	A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Managemen NCT04912869	Hoffmann-La Roche	Phase 1
Completed	Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease NCT05098028	Bausch Health Americas, Inc.	Phase 2
Completed	Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients NCT05255445	Westat	—
Completed	A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treat NCT05075824	Hoffmann-La Roche	Phase 2
Active Not Recruiting	Sickle Cell Disease Obstetric Multi-Disciplinary Care Programme NCT05143021	Vanderbilt University Medical Center	—
Active Not Recruiting	A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RIS NCT05031780	Agios Pharmaceuticals, Inc.	Phase 2 / Phase 3
Completed	A Study to Learn About Sickle Cell Disease In Adult Patients NCT05407805	Pfizer	—
Completed	Functional and Mechanistic Characterization of Limb Ulcers in Patients With Sickle Cell Disease NCT04983654	Hospices Civils de Lyon	N/A
Terminated	Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals Wit NCT04930445	Pfizer	—
Unknown	Nasopharyngeal Bacterial Carriage and Antibiotic Resistance in Children With Sickle Cell Disease in Ile-De-Fra NCT05197205	Assistance Publique - Hôpitaux de Paris	N/A
Recruiting	Cutaneous Hydration Assessment in SCD NCT05210114	Enrico Novelli	N/A
Terminated	A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Parti NCT06503458	Sanguine Biosciences	—
Completed	Interest of Famotidine in Children With Sickle Cell Disease NCT05084521	Assistance Publique - Hôpitaux de Paris	Phase 2 / Phase 3
Completed	Algorithm for Apherisis Monitoring and Prescription Assistance in Sickle Cell Patients (ALGODREP) NCT04076683	Etablissement Français du Sang	N/A
Completed	Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients NCT05371184	Ain Shams University	Phase 4
Completed	Pilot Evaluation of a Motivational Interviewing Intervention Targeting Adherence Behaviors in Youth With Sickl NCT04877054	Johns Hopkins All Children's Hospital	N/A
Unknown	Severe Acute Respiratory Syndrome CoV 2 COVID-19 Survey and Vaccination Coverage in the Sickle Cell Population NCT05153044	Assistance Publique - Hôpitaux de Paris	N/A
Completed	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir NCT05169580	Fulcrum Therapeutics	Phase 1
Terminated	A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Rec NCT04927247	Pfizer	Phase 3
Completed	COVID-19 Vaccine Response in Sickle Cell Disease NCT05139992	ASH Research Collaborative	—
Recruiting	RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs) NCT06213402	Hospital Universitari Vall d'Hebron Research Institute	—
Completed	Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease NCT04906447	University of Illinois at Chicago	Phase 2
Completed	Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease NCT04817670	Vifor (International) Inc.	Phase 2
Recruiting	Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease NCT04819841	Kamau Therapeutics	Phase 1 / Phase 2
Terminated	Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Cou NCT05020873	Novartis Pharmaceuticals	—
Completed	Red Blood Cell Survival in Sickle Cell Disease NCT04426591	Marianne Yee	Phase 1
Completed	Home-Based Intervention for Chronic Pain in Adults With Sickle Cell Disease NCT04906707	Emory University	N/A
Recruiting	Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Init NCT05635266	Sanguine Biosciences	—
Completed	Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Dat NCT06662812	Novartis	—
Completed	A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing NCT04935879	Pfizer	Phase 3
Completed	Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition NCT04754711	Centre Hospitalier Régional d'Orléans	N/A
Recruiting	Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease NCT05012631	Children's Hospital Medical Center, Cincinnati	Phase 2
Completed	Fitness Trial in Adults With Sickle Cell Disease (SCD Fit): A Feasibility Study NCT04772391	Memorial Healthcare System	N/A
Completed	Characteristics of Patients With Sickle Cell Disease NCT05494541	Novartis Pharmaceuticals	—
Completed	Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary NCT05833022	Novartis Pharmaceuticals	—
Completed	Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease NCT05392101	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Phase 2
Completed	Observational Prospective Study Measuring the Impact of the Use of a Hypnotic Script Associated With Virtual R NCT04917120	Assistance Publique - Hôpitaux de Paris	N/A
Withdrawn	US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease NCT04594031	ExCellThera inc.	Phase 1
Recruiting	A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD NCT04201210	University of Regensburg	Phase 2
Recruiting	Metabolic and Hemodynamic Reserve in Pediatric SCA NCT04406818	Washington University School of Medicine	N/A
Active Not Recruiting	Integrative Medicine in Pain Management in Sickle Cell Disease NCT05045820	Indiana University	N/A
Completed	Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial NCT04839354	Claudia R. Morris	Phase 3
Recruiting	Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizum NCT04657822	Novartis Pharmaceuticals	Phase 4
Unknown	Preservation and Transfer of HBV Immunity After Allogeneic HSCT for SCD NCT05200338	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	N/A
Unknown	Prevalence and Pathophysiology of Systemic Arterial Pressure Abnormalities in Childhood Sickle Cell Disease NCT04911049	Assistance Publique - Hôpitaux de Paris	—
Completed	A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD) NCT04983264	Pfizer	Phase 1
Completed	Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease NCT04285827	CSL Behring	Phase 1
Active Not Recruiting	Stroke Prevention in Young Adults With Sickle Cell Anemia NCT04808778	Vanderbilt University Medical Center	—
Completed	Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia NCT04380610	University of Alabama at Birmingham	—
Active Not Recruiting	A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) NCT04853576	Editas Medicine, Inc.	Phase 1 / Phase 2
Recruiting	A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease NCT04484272	University of Florida	N/A
Completed	Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease NCT04476277	National Heart, Lung, and Blood Institute (NHLBI)	EARLY_Phase 1
Recruiting	AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depl NCT04099966	Mitchell Cairo	Phase 2
Completed	Retrospective Real World Oxbryta® Data Collection and Analysis Study NCT04930328	Pfizer	—
Completed	Avascular Bone Necrosis in Sickle Cell Disease: a Pediatric Study. NCT05203991	San Luigi Gonzaga Hospital	—
Completed	DREPAMASSE Study - Evaluation of a Newborn Screening for Sickle Cell Disease by Tandem Mass Spectrometry NCT03985501	Hospices Civils de Lyon	—
Terminated	A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease NCT04335721	University of Illinois at Chicago	Phase 1 / Phase 2
Completed	Evaluation of Virtual Reality to Save Morphinic in the Treatment of Vaso-occlusive Seizures of Sickle Cell Pat NCT04756375	Assistance Publique - Hôpitaux de Paris	N/A
Active Not Recruiting	The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD. NCT04691323	Ann & Robert H Lurie Children's Hospital of Chicago	N/A
Completed	Obesity in Pediatric Sickle Cell Disease: A New Phenomenon NCT04676113	University of Mississippi Medical Center	—
Completed	Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT NCT04629430	University of Virginia	N/A
Completed	Vitamin D Status in Children With Sickle Cell Disease Living in Lyon, France NCT04694976	Hospices Civils de Lyon	—
Completed	Safety Evaluation of DREPADOM - Home Care Services and Hospitalizations for Sickle Cell Disease Patients NCT05649280	Soutien aux Actions contre les Maladies du Globule Rouge	—
Active Not Recruiting	A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) NCT04624659	Forma Therapeutics, Inc.	Phase 3
Completed	Building Adaptive Coping and Knowledge to Improve Daily Life NCT04602728	Emory University	N/A
Completed	Sickle Cell Anemia WE CARE NCT03716726	Boston Medical Center	N/A
Enrolling By Invitation	A Long-term Follow-up Study in Participants Who Received CTX001 NCT04208529	Vertex Pharmaceuticals Incorporated	Phase 3
Completed	SELF-BREATHE RCT for Chronic Breathlessness NCT04574050	King's College Hospital NHS Trust	N/A
Unknown	Primary Prevention of Stroke in Children With Sickle Cell Anaemia in Nigeria in the Community NCT05434000	Barau Dikko Teaching Hospital	N/A
Completed	Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients NCT04684381	Emmaus Medical, Inc.	Phase 4
Unknown	Evaluation of Left Ventricular Function by Speckle Tracking Echocardiography in Patient Hospitalised in Intens NCT04864041	Bicetre Hospital	—
Withdrawn	Medication Adherence and Non-adherence in Adults With Rare Disease NCT04541875	Xperiome	—
Completed	Evaluation of Therapeutic Adherence to Inciting Spirometry in Sickle Cell Patients NCT04667325	Centre Hospitalier Intercommunal Creteil	—
Withdrawn	Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies NCT04776850	M.D. Anderson Cancer Center	EARLY_Phase 1
Completed	Actigraphy Improvement With Voxelotor (ActIVe) Study NCT04400487	Pfizer	Phase 4
Recruiting	Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders NCT04416178	St. Jude Children's Research Hospital	—
Active Not Recruiting	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With St NCT04610866	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1 / Phase 2
Completed	Utilizing A Single Session Problem-Solving Intervention With Caregivers of Pediatric Patients Receiving Chroni NCT04606160	University of Texas Southwestern Medical Center	N/A
Completed	A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants NCT05036512	Pfizer	Phase 1
Withdrawn	Isoquercetin in Sickle Cell Anemia NCT04474626	Jeffrey Zwicker, MD	Phase 2
Recruiting	Integrative Diagnosis for SCD and Other RADs NCT07206095	Hospital Universitari Vall d'Hebron Research Institute	—
Recruiting	Exercise in Child Health NCT05359991	University of California, Irvine	N/A
Terminated	Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease NCT04218084	Pfizer	Phase 3
Completed	Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disea NCT04514510	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2
Terminated	COVID-19 Testing in Underserved and Vulnerable Populations NCT05315908	Jesse Nodora	N/A
Completed	Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease NCT04584528	Duke University	N/A
Completed	Safety, Tolerability and Pharmacokinetics of FTX-6058 NCT04586985	Fulcrum Therapeutics	Phase 1
Enrolling By Invitation	Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy NCT04628585	Genetix Biotherapeutics Inc.	—
Completed	Role of Inflammasome in Platelet Activation in Sickle Cell Disease Patient NCT06986837	Centre Hospitalier Universitaire de la Guadeloupe	—
Completed	Links Between Cognitive Functions and Clinical, Biological and Neuroradiological Outcomes in Adults With Sickl NCT04244240	Hospices Civils de Lyon	—
Enrolling By Invitation	The BENeFiTS Trial in Beta Thalassemia Intermedia NCT04432623	Phoenicia BioScience	Phase 1 / Phase 2
Recruiting	ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders NCT04398628	American Thrombosis and Hemostasis Network	—
Recruiting	An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease NCT04688411	Ann & Robert H Lurie Children's Hospital of Chicago	N/A
Completed	Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric NCT04388241	Children's National Research Institute	N/A
Completed	Daily Vitamin D for Sickle-cell Respiratory Complications NCT04170348	Columbia University	Phase 2
Completed	Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait NCT04349189	National Heart, Lung, and Blood Institute (NHLBI)	—

Showing the 300 most recent trials. Use search for older records.